Now available: Small, cost-effective liquid biopsy NGS assay
AmoyDx® HRR Liquid NGS Panel: Detection of mutations in 24 genes
The AmoyDx® HRR Liquid NGS Panel (RUO) is an NGS assay for the qualitative detection of mutations (SNVs, InDels) in 20 HRR genes as well as PTEN, AKT1, PIK3CA and AR on cfDNA from blood plasma. The small, cost-effective panel covers the most important HRR genes including all genes mentioned in the S3 guideline “Prostate cancer”, version 7.0, May 2024 in the context of a PARPi therapy [1].
The library is prepared using the hybrid capture method (ddCAP technology) over two days and the sequence data is analyzed locally by the AmoyDx® NGS Data Analysis System (ANDAS).
For more information, please click here.
Alternatively, you can contact us directly at molpath@zytomed-systems.de
Stay tuned for more liquid biopsy products coming soon.
[1] S3-Leitlinie Prostatakarzinom Version 7.0 – Mai 2024 AWMF-Registernummer: 043-022OL
Further topics
ZytoMax is now the exclusive distributor of AmoyDx® products in Switzerland
We are delighted to inform you that due to the positive customer response, the molecular diagnostic products of our partner AmoyDx® are now available to our customers in Switzerland through ZytoMax Schweiz GmbH, a sister company of Zytomed Systems GmbH.
Product update: BRCA1 and BRCA2
The new AmoyDx® BRCA Pro Panel is an improved version of the AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit. Both kits enable analysis of the entire coding regions of the BRCA1 and BRCA2 genes, and of exon/ intron boundries in DNA from FFPE specimen and from peripheral whole blood.
